Advertisement

Topics

Pfizer CEO Has Knack For Making A Profit, But He Misplayed The Optics Of Raising Prices In Current Atmosphere

08:41 EDT 13 Jul 2018 | Kaiser Health News

Like clockwork, Pfizer has been raising prices every six months, flying under the radar because most pharma companies were doing the same. But then the company caught the attention of President Donald Trump, and everything changed. In other pharmaceutical news: Novartis ditches antibiotics research; a patient advocacy group highlights a New Jersey candidate's ties to high prices; and an experimental epilepsy drug moves forward toward approval.

Original Article: Pfizer CEO Has Knack For Making A Profit, But He Misplayed The Optics Of Raising Prices In Current Atmosphere

NEXT ARTICLE

More From BioPortfolio on "Pfizer CEO Has Knack For Making A Profit, But He Misplayed The Optics Of Raising Prices In Current Atmosphere"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...